Neurology & CNS Licensing Deal Benchmarks 2026

Alzheimer's (Phase 2)

$3.5B

Disease-modifying mAb

Parkinson's (Phase 2)

$3.1B

Disease-modifying SM

Pain (Phase 2)

$2.1B

Symptomatic treatment

Neurology Royalties

12.8%-20.5%

Base tier range

Model Your Deal

Market Analysis

The neurology and CNS licensing landscape in 2026 is characterized by renewed optimism following breakthroughs in Alzheimer's disease-modifying therapies and advances in blood-brain barrier penetration technologies. Alzheimer's Phase 2 deals lead in deal value at $3.5B median, while Parkinson's disease-modifying approaches command $3.1B. Pain therapeutics remain active at $2.1B with differentiated non-opioid mechanisms.

CNS deal structures are distinctively milestone-weighted compared to oncology, reflecting longer development timelines, complex clinical endpoints (cognitive scales, functional assessments), and historically lower approval rates. Disease-modifying therapies carry the highest milestone potential due to the extended pivotal trial durations (3-5 years) and the transformative commercial opportunity if endpoints are met.

Royalty rates in neurology licensing range from 12.8% to 20.5% at the base tier, with variations driven by BBB penetration data, disease-modification evidence, and competitive positioning. Key valuation differentiators unique to CNS include demonstrated brain penetration, biomarker-based patient selection, and pathway de-risking through novel clinical trial designs.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do neurology deal terms compare to oncology?

Neurology deal total values are generally competitive with oncology when comparing equivalent stages and modalities. However, neurology deals allocate a higher proportion to milestones due to longer development timelines and higher clinical risk. Alzheimer's Phase 2 deals ($3.5B) are comparable to many oncology Phase 2 transactions.

What neurology indications command the highest deal values?

Alzheimer's disease-modifying therapies lead at $3.5B, followed by Parkinson's disease ($3.1B) and novel pain therapies ($2.1B). Rare neurological disorders can command premium valuations through orphan drug pathways.

What role does BBB penetration play in CNS deal valuations?

Blood-brain barrier penetration is a critical valuation driver in CNS deals. Assets with proven CNS penetration command 20-30% premium over those with unproven BBB data. Novel BBB delivery platforms (including brain shuttle technologies and focused ultrasound approaches) are attracting significant platform deal interest.

What trends are shaping neurology licensing in 2026?

Key trends include growing deal activity in disease-modifying neurodegeneration therapies, emergence of psychedelic-derived therapeutics for psychiatric conditions, increased interest in digital biomarker endpoints, and platform deals for BBB delivery technologies. Gene therapy and ASO approaches for rare neurological diseases are also commanding premium terms.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Neurology & CNS Licensing Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Alzheimer's Disease Deals

Gene Therapy Deals

Oncology Deal Overview 2026

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?